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Creatine kinase (CK) has been associated with reduced inflammation in obesity while
inflammation is associated with obesity-related cardiovascular diseases. We investigated
the relationship between CK and high sensitive C-reactive protein (hs-CRP) in a general
population.
Methods
CK and hs-CRP were measured in the population-based Tromsø study that included entire
birth cohorts and random samples of citizens between 30–87 years of age. The analyses
were performed sex-stratified in 5969 men and 6827 women.
Results
CK correlated negatively with hs-CRP in men (r = -0.08, P <0.001) and women (r = -0.06,
P <0.001). In univariable regression analyses, CK associated negatively with hs-CRP in
men (ß = -0.14, 95% CI -0.19 to -0.10, P <0.001) and women (ß = -0.13, 95% CI -0.18 to
-0.08, P <0.001). Mean CK declined from the 2. to the 4. quartiles of hs-CRP in both genders
(P <0.001 for trends). There were positive correlations between CK and body mass index
(BMI) in men (r = 0.10, P <0.001) and women (r = 0.07, P <0.001). Multiple regression analy-
ses showed a 0.13 unit decrease in hs-CRP (mg/dl) per unit CK increase in men (95% CI
-0.35 to -0.20) and 0.29 mg/dl in women (95% CI -0.36 to -0.21) when adjusted for age, BMI,
lipids, s-glucose, s-creatinine, transaminases and coronary heart disease.
Conclusion
CK were inversely and independently associated with hs-CRP in a general population.
These data provide evidence that CK might have anti-inflammatory properties, but the
mechanism and clinical implications are unclarified.
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Introduction
Creatine kinase (CK), an enzyme promoting cellular energy metabolism mainly in skeletal
muscles, has been associated with inflammation. Mechanisms to explain this are not estab-
lished, but obesity is a possible link [1]. Plasma levels of inflammatory biomarkers predict
obesity [2–4], and obesity-related inflammation is associated with increased risk of cardio-
vascular diseases (CVD) and CVD-mortality [5]. Pro-inflammatory metabolites (adipokines)
produced by adipocytes seem to be an important mechanism [6], but there is additional evi-
dence for a contribution of skeletal muscle in the inflammatory process related to obesity [7].
As opposed to adipocytes, release of biologically active metabolites (myokines) from myo-
cytes has been related to reduced obesity-related inflammation [8]. There is therefore a possi-
ble interaction or “crosstalk” between myocytes and adipocytes involved in the process of
adiposity [9, 10].
CK is associated with body mass index (BMI) in population-based studies [11, 12] and in a
case-control study primarily designed to investigate the relationship between CK and blood
pressure [13]. Inflammatory markers in obese women with reduced muscle mass and
increased fat mass (sarcopenic obesity) were associated with higher CK [14]. Inflammation
representing a shared mechanism for release of CK to the circulation may be attributed to
physical activity. Accordingly, a higher CK-response was observed after performing eccentric
exercise in elderly obese subjects with increased level of interleukin 6 [15]. Furthermore, CK
along with lean mass were inversely and independently associated with C-reactive protein
(CRP) in a sample of 454 overweight and obese individuals, supporting an anti-inflammatory
role for CK [1]. Studies about how CK activity at rest associates with inflammation should also
include non-obese populations. We therefore hypothesized an independent relationship
between CK and CRP in the general population.
Material and methods
Study participants
This project is based on data from the 6th Tromsø Study, a prospective population-based study
that started in 1974. Originally, the Tromsø Study focused on CVD risk factors, but a number
of variables linked to a variety of issues have been included since then [16]. Participants in a
previous survey (4th Tromsø study), a 10% random sample from age groups 30–39, all partici-
pants aged 40–42 and 60–87. The data were collected from October 2007 to 19 September
2008. Totally, 12984 men and women participated. The population was mainly Causation
(87.3% ethnic Norwegians, 1.6% of Sami ethnicity, 1.3% of Finnish origin, 2.2% of other eth-
nicities, and 7.6% without information about ethnicity) [16]. Written consent was obtained
from all participants, and the Norwegian Committee for Medical and Health Research Ethics
(REC) approved the study.
Measurements
Hs-CRP was analysed in thawed aliquots after storage at − 20 ˚C with a particle-enhanced
immunoturbidimetric assay on a Modular P (Roche Hitachi, Mannheim, Germany), with
reagents from Roche Diagnostics (Mannheim, Germany). Samples were analysed in batches
during the time of the survey. The lower detection limit of the high-sensitivity CRP assay was
0.03 mg /L and measurements of CRP lower than 0.03 mg /L were set at this value. The analyti-
cal coefficient of variation for CRP levels between 0.1 mg /L and 20 mg /L was < 4%.
Serum-CK was analysed consecutively within 6 hours after the phlebotomies in an auto-
mated clinical chemistry analyzer (Modular P, Roche) by photometry, using an enzymatic
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method (CK-NAC, Roche Diagnostics, Mannheim, Germany). The analytic variation coeffi-
cient was  1.6%. The standard cut-off limits for CK developed by the Nordic Reference
Interval Project (NORIP) were: Men between 18–50 years (50–400 U/L); Men  50 years
(40–280 U/L); Women (35–210 U/L) [17]. Men (N = 7) and women (N = 16) with
CK 1000 U/L were regarded as outliers and therefore excluded. Non-fasting S-glucose was
obtained. Determination of glycosylated hemoglobin (HbA1C) in EDTA whole blood was
based on an immunoturbidometric assay (UNIMATES, F. Hoffmann-La Roche AG). The
HbA1c percent value was calculated from the HbA1C/Hb ratio. Serum total cholesterol was
analysed by an enzymatic colorimetric method using a commercially available kit (CHOD-
PAP, Boehringer-Mannheim, Mannheim, Germany). Serum high-density lipoprotein
(HDL) cholesterol was measured after precipitation of lower-density lipoproteins with hepa-
rin and manganese chloride. All the analyses were done at the Department of Clinical Bio-
chemistry, University Hospital of North Norway. According to the standard procedure in
the Tromsø study, height and weight were measured wearing light clothing without shoes to
the nearest 0.1 cm and 0.1 kg using an automatic device, and BMI calculated as weight (kg)
divided by height squared (m2). Waist- and hip circumference were measured and waist-to-
hip ratio calculated. Information on diabetes, use of lipid-lowering drugs and coronary
heart disease was obtained from standard questionnaires in the Tromsø study. Coronary
heart disease was registered as a case when participants reported previous heart attack.
Hypertension was defined as systolic blood pressure  140 mmHg, diastolic blood
pressure 90 mmHg or ever use of antihypertensive drugs. Diabetes was defined as
HbA1c 6.5% or use of antidiabetic drugs.
Statistical analysis
We performed the statistical analysis using SPSS software version 23 (SPSS INC, Chicago, Illi-
nois, USA). Endpoint variables were visually inspected by histograms, and kurtosis and skew-
ness calculated to ascertain normal distribution. The histograms showed right-sided skewness
in both variables for men and women. Serum CK (men: skewness 2.7, kurtosis 11.9; women:
skewness 3.7, kurtosis 25.4) and hs-CRP (men: skewness 7.5, kurtosis 82.8; women: skewness
9.5, kurtosis 167.0) confirmed non-Gaussian distribution of the data. Subsequent analyses of
log CK (men: skewness 0.4, kurtosis 0.5; women: skewness 0.5, kurtosis 1.2) and log hs-CRP
(men: skewness 0.7, kurtosis 0.7; women: skewness 0.5, kurtosis 0.2) and inspection of histo-
grams showed normal distribution of the variables. We therefore used log-transformed data
for CK and hs-CRP in the analyses.
Descriptive data are presented as mean ± standard deviations (SD) or numbers and fre-
quencies in men and women separately. Two-sided Student´s t-test was used to calculate
differences between means and χ2- test to compare frequencies of data within groups
(dichotomous data). Due to different cut-off levels of CK, its association to hs-CRP were
analysed separately for men and women. To assess linear trends of CK across quartiles of
hs-CRP, we used ANOVA. By multiple regression analysis, possible confounders were
tested and adjusted for with hs-CRP as the dependent variable and CK, age, BMI, HDL- and
LDL-cholesterol [18], s-glucose [19], creatinine, transaminases and coronary heart disease
[20] as independent variables. The independent variables were included in the multivariable
model if reported in the literature as associated with CRP or appeared significantly related
to CRP in univariable regression analyses in the present samples. Repeated tests replacing
BMI with alternative obesity-parameters (waist circumference and hip-to-waist ratio) were
performed to further elucidate associations with obesity. The level of significance was set at
5%.
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Results
In this population, men and women were of the same age, but men had higher scores on obe-
sity-parameters than women (Table 1). About 20% of both sexes were obese (Table 1). Log CK
and log hs-CRP were higher in men, and men more commonly reported coronary heart dis-
ease (heart attack), diabetes, hypertension and use of lipid-lowering drugs than women did
(Table 1). Mean CK (SD) in male participants currently using lipid-lowering drugs was 2.09
(0.22) U/L (n = 992) compared to 2.10 (0.23) U/L in the others (n = 4977, P = 0.17). The corre-
sponding values for women were 1.94 (0.20) U/L (n = 845) vs. 1.94 (0.21) U/L in others
(n = 5982, P = 0.62). There were positive correlations between CK and BMI in (r = 0.10,
P<0.0001) and women (r = 0.07, P<0.0001).
CK correlated negatively with hs-CRP in both genders (Figs 1 and 2). Univariable linear
regression analyses showed CK to be negatively associated with hs-CRP in men and women
(P<0.0001) (Table 2). Conversely, obesity-parameters, s-glucose and HbA1C were positively
associated with hs-CRP. S-total cholesterol and LDL cholesterol were positively associated
with hs-CRP in women only, while HDL-cholesterol associated negatively with hs-CRP in
both genders (Table 2). Mean hs-CRP (SD) in men with coronary heart disease was 0.20 (0.43)
Table 1. Clinical characteristics of the subjects presented as numbers (%) or mean (SD).
Variables Men (n = 5969) Women (n = 6827) P
Age (years) 57.4 (12.3) 57.4 (13.0) 1.0
Height (cm) 176.9 (6.9) 163.3 (6.5) <0.0001
Weight (kg) 85.4 (13.3) 70.9 (13.0) <0.0001
BMI (kg/m2) 27.3 (3.8) 26.6 (4.7) <0.0001
Waist circumference (cm) 99.5 (10.6) 90.9 (12.2) <0.0001
Hip circumference (cm) 104.4 (6.6) 103.9 (9.1) 0.001
Waist-to-hip ratio 0.95 (0.07) 0.87 (0.09) <0.0001
Obesity (BMI30 kg/m2) 1234 (20.7) 1397 (20.5) 0.69
Diabetes mellitus, n (%) 327 (5.5) 306 (4.5) 0.01
Use of lipid lowering drugs 992 (16.6) 845 (12.4) <0.0001
Hypertension 2083 (34.6) 1949 (28.6) <0.0001
Coronary heart disease 482 (8.1) 199 (2.9) <0.0001
S-creatinine (μmol/l) 78.7 (15.9) 62.7 (12.5) <0.0001
S-glucose (mmol/l) 5.38 (1.38) 5.12 (1.05) <0.0001
S-HbA1C (%) 5.70 (0.71) 5.60 (0.60) <0.0001
S-total cholesterol (mmol/l) 5.50 (1.06) 5.70 (1.11) <0.0001
S-HDL-cholesterol (mmol/l) 1.35 (0.38) 1.65 (0.44) <0.0001
S-LDL-cholesterol (mmol/l) 3.56 (0.93) 3.55 (0.97) 0.63
S-CK (U/L) 147.8 (96.2) (IQR12.0–981.0) 98.6 (60.1) (IQR10.0–871.0) <0.0001
Log CK (U/L) 2.10 (0.23) 1.94 (0.20) <0.0001
High CK a 319 (5.3) 276 (4.0) <0.0001
Hs-CRP (mg/dl) 2.5 (4.7) (IQR 0.1–82.9) 2.5 (4.6) (IQR 0.1–136.6) 0.66
Log hs-CRP (mg/dl) 0.15 (0.41) 0.14 (0.44) 0.01
S-ALT (U/L) 32.6 (19.4) 26.3 (25.6) <0.0001
S-AST (U/L) 27.9 (10.0) 25.3 (14.2) <0.0001
CK, creatine kinase; hs-CRP, high sensitive C-reactive protein; BMI, body mass index; HDL, high-density lipoprotein; LDL; low-density lipoprotein; ALT, alanine
transaminase; AST, aspartate transaminase
a Reference limits for normal CK: Men < 50 years: 50–400 U/L, men 50 years: 40–280 U/L, women: 35–210 U/L
https://doi.org/10.1371/journal.pone.0198133.t001
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mg/dl compared to 0.15 (0.41) mg/dl in the others (P = 0.006). The female data were 0.21
(0.41) mg/dl respectively 0.13 (0.44) mg/dl (P = 0.005). Diabetes mellitus and creatinine were
not associated with hs-CRP or CK (data not shown).
CK declined significantly from quartiles 2 to 4 of hs-CRP in both sexes (Table 3) and CK
was inversely and independently associated with hs-CRP in men and women when adjusted
for age, BMI, glucose, creatinine, transaminases, lipids and coronary heart disease (Table 4). In
men, a 1-unit increase in CK was associated with 0.13 mg/dl lower hs-CRP (95% CI -0.35 to
-0.20). In women, the corresponding values were 0.29 mg/dl (95% CI -0.36 to -0.21). A multi-
variable-adjusted sensitivity analysis excluding participants with incidents of coronary heart
disease (men: n = 482; women: n = 199) did not change the results (data not shown). Neither
did inclusion of LDL-cholesterol (replacing HDL-cholesterol) or waist circumference and
waist-to-hip ratio (replacing BMI) change the results (data not shown). Mean (SD) hs-CRP in
the male subgroup with self-reported coronary heart disease (n = 482) was 0.20 mg/dl (0.43)
compared to 0.15 mg/dl (0.41) in the others (n = 5487, P = 0.006). The equivalent data for
women (n = 199) were 0.21 mg/dl (0.41) vs. 0.13 mg/dl (0.44), (n = 6628, P = 0.008). CK corre-
lated with creatinine in men (r = 0.047, P< 0.001) and women (r = 0.113, P< 0.001).
Fig 1. Correlation between creatine kinase (CK) and high sensitive C-reactive protein (hs-CRP) in 5969 men from a general
population.
https://doi.org/10.1371/journal.pone.0198133.g001
Creatine kinase and inflammation
PLOS ONE | https://doi.org/10.1371/journal.pone.0198133 May 29, 2018 5 / 11
Additionally, CK correlated inversely with glucose in men (r = -0.037, P< 0.001) but not in
women (r = 0.009, P = 0.48).
Discussion
This study demonstrated an inverse and significant association between CK and hs-CRP in the
general population. After adjusting for obesity-related variables, s-glucose, HbA1C, creatinine,
transaminases and lipids, CK remained independently associated with hs-CRP. CK may hypo-
thetically inhibit inflammation in humans, but the mechanism and clinical implications are
uncertain.
This result parallels the finding in a previous clinical study comparing CK and CRP in
obese individuals [1]. In that study, which motivated the present one, CK and lean body mass
were negatively associated with CRP indicating an inhibitory effect on obesity-related inflam-
mation by CK and/or by other muscular metabolites [1]. The present study therefore supports
an inverse relationship between CK and CRP by its presence in the general population, but an
influence of obesity is not confirmed from these data. Nevertheless, BMI was associated with
Fig 2. Correlation between creatine kinase (CK) and high sensitive C-reactive protein (hs-CRP) in 6827 women from a general
population.
https://doi.org/10.1371/journal.pone.0198133.g002
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elevated CK as proven by others [11], and CRP was positively associated with BMI. In a recent
report, CK was inversely associated with fat mass in obese subjects indicating a favourable role
for CK in the process of adiposity [21]. In subsequent studies, body composition examinations
comparing body fat and lean mass with CRP should be performed in general populations to
further elucidate the mechanism(s). BMI may fail to predict obesity because it does not distin-
guish between fat and muscle content [22, 23]. Nor does it reflect body fat distribution. Like-
wise, those with increased adipose tissue and reduced muscle mass (sarcopenic phenotype) are
at risk of adverse outcome, but may be overlooked when using BMI as an obesity marker [24].
The cascade of events leading to atherosclerosis and CVD is complex, but macrophage
influx in adipose tissue with local inflammation [25], release of adipokines [26] and liver-
induced CRP are important reactions. In the present study, hs-CRP was positively associated
with BMI confirming findings from prior reports [27, 28]. Hs-CRP was also higher in partici-
pants with coronary heart disease. In studies with examination of body composition, inflam-
mation has been positively associated with fat mass and negatively associated with lean mass
Table 2. Associations between hs-CRP, CK and potential confounders.
Log hs-CRP in men (mg/dl) Log hs-CRP in women (mg/dl)
ß a (95% CI) P ß a (95% CI) P
Log CK (U/L) -0.14 (-0.19 to -0.10) <0.0001 -0.13 (-0.18 to -0.08) <0.0001
Age (years) 0.005 (0.005 to 0.006) <0.0001 0.007 (0.006–0.007) <0.0001
BMI (kg/m2) 0.029 (0.026 to 0.031) <0.0001 0.040 (0.038 to 0.042) <0.0001
Waist circumference (cm) 0.011 (0.010 to 0.012) <0.0001 0.015 (0.014 to 0.016) <0.0001
Waist-to-hip ratio 0.011 (0.010 to 0.012) <0.0001 1.93 (1.79 to 2.08) <0.0001
S-gluccose (mmol/l) 0.022 (0.015 to 0.030) <0.0001 0.058 (0.049 to 0.068) <0.0001
S-HbA1C (%) 0.099 (0.084 to 0.114) <0.0001 0.173 (0.156 to 0.190) <0.0001
S-total-cholesterol (mmol/l) 0.004 (-0.006 to 0.014) 0.43 0.036 (0.027 to 0.045) <0.0001
S-HDL-cholesterol (mmol/l) -0.193 (-0.220 to -0.165) <0.0001 -0.231 (-0.255 to -0.208) <0.0001
S-LDL-cholesterol (mmol/l) 0.010 (-0.001 to 0.022) 0.071 0.055 (0.044 to 0.066) <0.0001
S-creatinine (μmol/l) 0.002 (0.001–0.002) <0.0001 0.002 (0.001–0.003) <0.0001
S-ALT (U/L) 0.002 (0.001–0.003) <0.0001 0.002 (0.001–0.002) <0.0001
S-AST (U/L) 0.003 (0.002–0.005) <0.0001 0.003 (0.002–0.004) <0.0001
CK, creatine kinase; hs-CRP, high sensitive C-reactive protein; BMI, body mass index; HDL, high-density lipoprotein; LDL; low-density lipoprotein; ALT, alanine
transaminase; AST, aspartate transaminase
a The regression coefficient (ß) and 95% CI expressed in mg/dl for a 1-unit increase in continuous variables
https://doi.org/10.1371/journal.pone.0198133.t002
Table 3. CK in quartiles of hs-CRP.
Log hs-CRP quartiles (mg/dl)
Q 1 Q 2 Q 3 Q 4 P for trend
N (men) 1502 1484 1464 1519
Log hs-CRP (mg/dl) -0.14 -0.13–0.10 0.11–0.38 0.39
Log CK (U/L) 2.11 (0.21) 2.11 (0.23) 2.10 (0.23) 2.08 (0.22) <0.0001 a
N (women) 1687 1717 1718 1705
Log hs-CRP (mg/dl) -0.20 -0.19–0.09 0.10–0.41 0.42
Log CK (U/L) 1.95 (0.20) 1.95 (0.21) 1.94 (0.21) 1.92 (0.22) <0.0001 a
CK, creatine kinase; hs-CRP, high sensitive C-reactive protein, Q1, first quartile; Q2, second quartile; Q3, third quartile; Q4, fourth quartile, CI; confidence interval
a The trends analysed by ANOVA were significant from quartiles 2 to 4
https://doi.org/10.1371/journal.pone.0198133.t003
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[7]. In a longitudinal cohort study, high CRP and interleukin (IL)-6 were associated with loss
of lean mass [29]. Studies on the relationship between CK and adipokines have been reported
in relation to muscle exercise [15], but not at rest in obesity or in the general populations.
Thus, adipocyte/myocyte activity may be integrated. Myokines such as myostatin, IL-4, -6, -7,
-15 are probably involved in the local energy metabolism in brown fat [30, 31]. Impact of lean
mass on obesity in younger age groups without sarcopenic obesity is less investigated. Further-
more, skeletal muscle is an important site of insulin action, and increased lean mass is associ-
ated with better insulin sensitivity and reduced inflammation [32]. CK plays an important role
in the cellular energy metabolism in skeletal muscle, and additionally, creatine enhances respi-
ration rate in brown adipocyte mitochondrion, and thereby increases cellular heat and energy
expenditure [33]. This indicates a possible mechanism for how CK might interfere with obe-
sity, and why it is worth hypothesizing an association between CK and inflammation. CK has
not been measured in fat tissue, however.
High CK may have many causes [34] and it is important to control for contributing effects
of accompanying disorders. Earlier studies focusing on conditions associated with hyperCKe-
mia and inflammation show that high CK may possibly be explained by inflammatory myopa-
thies in some cases [35]. Such diseases are rare in general populations however, and they
seldom go unrecognized because of typical symptoms. Additionally, CK showed lower values
in patients with inflammatory rheumatic diseases [36, 37]. Inflammatory activity, muscle mass
and steroid use were factors associated with reduced CK in one study [37]. These studies indi-
cate that inflammation may initiate a process leading to reduction in CK levels but the cause-
effect direction in the CK-CRP connection is still unknown, especially when it comes to the
relationship between CK and obesity. By excluding participants with CK 1000 U/L in this
study, we reduced the possibility of including patients with diseases that affect CK, such as
neuromuscular disorders and inflammatory conditions, but use of steroids or other com-
pounds with a potential to influence CK and CRP levels is unknown except for lipid-lowering
drugs. This population should therefore be well designed to study population aspects of CK
activity at rest, but lack of information about muscular strain prior to blood withdrawal in the
participants is nevertheless a limitation to the study. Hypothetically, inflammation may
Table 4. Associations between hs-CRP (dependent variable) and independent variables in men and women.
Log hs-CRP in men (mg/dl) Log hs-CRP in women (mg/dl)
ß (95% CI) P ß (95% CI) P
Log CK (U/L) -0.13 (-0.35 to -0.20) <0.0001 -0.29 (-0.36 to -0.21) <0.0001
Age 0.005 (0.004 to 0.007) <0.0001 0.004 (0.002 to 0.005) <0.0001
BMI 0.027 (0.022 to 0.032) <0.0001 0.037 (0.034 to 0.041 <0.0001
S-HDL-cholesterol (mmol/l) -0.14 (-0.18 to -0.09) <0.0001
S-LDL-cholesterol (mmol/l) 0.008 (-0.008 to -0.024) 0.34
S-glucose (mmol/l) 0.001 (-0.011 to 0.013) 0.86 0.019 (0.005 to 0.034) 0.01
Coronary heart disease -0.09 (-0.15 to -0.04) 0.001 -0.07 (-0.16 to -0.02) 0.14
S-creatinine (μmol/l) 0.001 (0.000 to 0.002) 0.007 0.001 (-0.001 to 0.002) 0.42
S-ALT (U/L) -0.001 (-0.002 to -0.005) 0.34 -0.001 (-0.003 to -0.000) 0.054
S-AST (U/L) 0.005 (0.002 to 0.007) <0.0001 0.004 (0.001 to 0.006) 0.003
R2 = 0.13 R2 = 0.19
CK, creatine kinase; hs-CRP, high sensitive C-reactive protein; BMI, body mass index; HDL, high-density lipoprotein; LDL; low-density lipoprotein; CI; confidence
interval; ALT, alanine transaminase; AST, aspartate transaminase
https://doi.org/10.1371/journal.pone.0198133.t004
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facilitate release of CK to the circulation, especially during muscular exertion [15]. Whether
CK exerts any direct role on reducing hs-CRP need experimental evidences.
Conclusion
CK and CRP were inversely related in men and women in the prospective population-based
Tromsø study. This supports the hypothesis that CK may have an anti-inflammatory effect,
but the direction of the relationship and clinical implications are yet to be investigated. CK
measurement should be considered in cases with inflammation of unknown origin.
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